Singapore, Aug. 7 -- Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) is collaborating with Hilleman Laboratories, a Singapore-based joint venture of biopharmaceutical company MSD and charitable foundation Wellcome, to advance the development and manufacturing of Bundibugyo ebolavirus vaccine candidate doses for clinical trials using the recombinant vesicular stomatitis virus (rVSV) platform.

With up to $8.5 million in CEPI funding, Hilleman Laboratories will advance development and manufacture clinical supply of the investigational vaccine at the organisation's vaccine production facility as scientists ramp up efforts to respond to one of the largest Ebola outbreaks on record, which is predominantly affecting the Demo...